ABSTRACT
Surgical interventions in patients with hemophilia (PWH) in the developing world are difficult in the setting of limited availability of factor concentrates. Although the adequacy of international guidelines for factor concentrate prophylaxis for PWH undergoing surgery has been established, frequently it is not practical in the developing world. These recommendations were not established based on large clinical trials and fail to define the safe lower limit of factor concentrate prophylaxis for surgery. The need to define these lower limits is essential in the developing world so that the limited resources may be used optimally for the cohort of PWH. There are limited data from the developing world with regard to PWH undergoing surgical procedures. In this article, we outline experience from our institution, a tertiary referral center for hemophilia care in India. We trace the basis on which our current factor concentrate prophylaxis regimen (which is lower than that recommended internationally) was established. In our experience our low-dose protocols are effective, reduce factor consumption by one third, and are not associated with a significantly increased risk of delayed hemorrhage. We hope that this experience will form a framework on which guidelines can be established for developing countries.
KEYWORDS
Hemophilia - surgery - developing world - low-dose protocols
REFERENCES
-
1
Srivastava A.
Choice of factor concentrates for haemophilia: a developing world perspective.
Haemophilia.
2001;
7
117-122
-
2
Srivastava A.
Factor replacement therapy in haemophilia-are there models for developing countries?.
Haemophilia.
2003;
9
391-396
-
3
Rickard K.
Guidelines for therapy and optimal dosage of coagulation for the treatment of bleeding and surgery in haemophilia.
Haemophilia.
1995;
1(suppl 1)
8-13
-
4
Bhushan V, Chandy M, Khanduri U, Dennison D, Srivastava A, Apte S.
Surgery in patients with congenital coagulation disorders.
Natl Med J India.
1994;
7
8-12
-
5
Kasper C K. Hemophilia of Georgia, USA .
Protocols for the treatment of haemophilia and von Willebrand disease.
Haemophilia.
2000;
6(suppl 1)
84-93
-
6
Kasper C K, Boylen A L, Ewing N P, Luck Jr J V, Dietrich S L.
Hematologic management of hemophilia A for surgery.
JAMA.
1985;
253
1279-1283
-
7
Srivastava A, Chandy M, Sunderaj G D et al..
Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia.
Haemophilia.
1998;
4
799-801
-
8
Martinowitz U P, Schulman S.
Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
Acta Haematol.
1995;
94(suppl 1)
35-42
-
9
Scharrer I.
Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Haemophilia.
1999;
5
253-259
-
10
Di Michele D M.
Immune tolerance: a synopsis of the international experience.
Haemophilia.
1998;
4
568-573
-
11
Rivard G E.
Use of protein-A column and porcine factor VIII.
Haemophilia.
2002;
8(suppl 1)
20-23
discussion 28-32
-
12
Preston F E, Dinsdale R C, Sutcliffe D J, Bardhan G, Wyld P J, Hamlyn J F.
Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors.
Thromb Res.
1977;
11
643-651
-
13
Rasche H, Bindewald H, Kohle W, Scheck R, Heinrich R, Seibert K.
Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates. [Author’s translation] .
Dtsch Med Wochenschr.
1977;
102
319-323
-
14
Thomas T, Williams H, Williams Y, Hunt J.
FEIBA in haemophiliacs with factor VIII inhibitor.
BMJ.
1977;
1
52
-
15
Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P.
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Thromb Haemost.
1997;
77
1113-1119
-
16
Batorova A, Martinowitz U.
Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery.
Br J Haematol.
2000;
110
715-720
-
17
Rochat C, McFadyen M L, Schwyzer R, Gillham A, Cruickshank A.
Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery.
Haemophilia.
1999;
5
181-186
-
18
Campbell P J, Rickard K A.
Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience.
Aust N Z J Med.
1998;
28
440-445
-
19
Hay C R, Doughty H I, Savidge G F.
Continuous infusion of factor VIII for surgery and major bleeding.
Blood Coagul Fibrinolysis.
1996;
7(suppl 1)
S15-S19
-
20
Morfini M, Messori A, Longo G.
Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
Blood Coagul Fibrinolysis.
1996;
7(suppl 1)
S11-S14
Alok SrivastavaM.D.
Professor, Department of Haematology
Christian Medical College, Vellore-632004, India
Email: aloks@cmcvellore.ac.in
